Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs BAY-2328065 (Primary) ; BAY-2328065 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Bayer
- 21 Jan 2019 Planned End Date changed from 4 Feb 2019 to 11 Feb 2019.
- 20 Dec 2018 Planned End Date changed from 15 Jan 2019 to 4 Feb 2019.
- 24 Oct 2018 Planned End Date changed from 9 Jan 2019 to 15 Jan 2019.